$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Side effects and treatment methods of XL184 in the treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and adverse reactions of rubitidine in the treatment of small cell lung cancer
2025-10-19 11:44:20
Check Details
The mechanism of acquiring resistance to crizotinib in ALK-rearranged lung cancer
2025-10-19 11:44:20
Check Details
Serious adverse reactions during treatment with crizotinib (Xalkori)
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and adverse reactions of ceritinib in the treatment of advanced ALK-positive lung cancer
2025-10-19 11:44:20
Check Details
The most common adverse reactions of nivolumab in the treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and side effects of ramucirumab in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
Side effects and treatment methods of alectinib in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and adverse reactions of alectinib in the treatment of ALK-positive lung cancer
2025-10-19 11:44:20
Check Details
Side effects and treatment methods when using lorlatinib to treat non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Side effects and treatment methods of Xalkori in the treatment of ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How many days will the side effects of Duozerun's treatment of lung cancer last?
2025-10-19 11:44:20
Check Details
1
2
...
4094
4095
4096
4097
4098
4099
4100
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
2
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
3
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
4
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
5
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
6
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
7
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
8
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
9
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
10
Vemurafenib (Zelboraf) Complete Medication Guide
11
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
12
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer